FindTrial
Sign In

Comparing blood inflammation levels in cancerous and non cancerous thyroid growths

A Comparative study of Systemic immune-inflammatory index in Benign and Malignant thyroid lesions - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/07/091215
Enrollment
88
Registered
2025-07-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E079- Disorder of thyroid, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil Intervention4: Nil: Nil Intervention5: Nil: Nil

Sponsors

Dr Bhavya Kalra
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergoing USG Neck (with TIRADS score) and FNAC (with Bethesda score) All patients from the above who undergo thyroidectomy (Hemi or Total)

Exclusion criteria

Exclusion criteria: Patients with Active or chronic infection Patients with diffuse toxic goitre Immunocompromised patients, patients with autoimmune diseases Patients who underwent head and neck radiation Pregnant patients Patients previously underwent thyroid surgery

Design outcomes

Primary

MeasureTime frame
Create a cut off value of SII with optimal sensitivity and specificity to aid in differentiating benign and malignant thyroid lesions (using an ROC curve) Timepoint: At index presentation—

Secondary

MeasureTime frame
Assessing the utility of SII in inderminate lesions (Bethesda 3,4 & TIRADS 3) Timepoint: At index presentation—

Countries

India

Contacts

Public ContactDr Pavan M Bhat

Kasturba Medical College, Manipal

rajgopal.shenoy@manipal.edu9845243460

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026